ZGNX Stock - Zogenix, Inc.
Unlock GoAI Insights for ZGNX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $81.69M | $13.64M | $3.65M | N/A | $9.82M |
| Gross Profit | $76.86M | $13.10M | $3.65M | N/A | $-908,000 |
| Gross Margin | 94.1% | 96.0% | 100.0% | N/A | -9.2% |
| Operating Income | $-212,032,000 | $-247,717,000 | $-429,821,000 | $-141,175,000 | $-119,936,000 |
| Net Income | $-227,413,000 | $-209,383,000 | $-419,503,000 | $-123,914,000 | $-126,817,000 |
| Net Margin | -278.4% | -1534.7% | -11499.5% | N/A | -1291.3% |
| EPS | $-4.24 | $-3.90 | $-9.74 | $-3.27 | $-4.65 |
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Visit WebsiteEarnings History & Surprises
ZGNXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2022 | Feb 28, 2022 | $-0.88 | $-0.98 | -11.4% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.98 | — | — |
Q4 2021 | Nov 4, 2021 | $-0.97 | $-1.04 | -7.2% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.93 | $-1.05 | -12.9% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-1.02 | $-1.00 | +2.0% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $-1.26 | — | — |
Q4 2020 | Nov 9, 2020 | $-0.98 | $-1.08 | -10.2% | ✗ MISS |
Q3 2020 | Aug 5, 2020 | $-1.00 | $-0.96 | +4.0% | ✓ BEAT |
Q1 2020 | Mar 2, 2020 | $-1.06 | $-1.26 | -18.9% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | — | $-1.26 | — | — |
Q4 2019 | Nov 7, 2019 | $-1.02 | $-6.75 | -561.8% | ✗ MISS |
Q3 2019 | Aug 6, 2019 | $-0.78 | $-0.89 | -14.1% | ✗ MISS |
Q2 2019 | May 8, 2019 | $-0.83 | $-0.83 | 0.0% | = MET |
Q4 2018 | Dec 31, 2018 | — | $-0.53 | — | — |
Q4 2018 | Nov 8, 2018 | $-0.88 | $-1.08 | -22.7% | ✗ MISS |
Q3 2018 | Aug 6, 2018 | $-0.87 | $-0.83 | +4.6% | ✓ BEAT |
Q2 2018 | May 9, 2018 | $-0.74 | $-0.87 | -17.6% | ✗ MISS |
Q4 2017 | Dec 31, 2017 | — | $-1.17 | — | — |
Q4 2017 | Nov 7, 2017 | $-0.93 | $-1.68 | -80.6% | ✗ MISS |
Q3 2017 | Aug 8, 2017 | $-0.88 | $-0.93 | -5.7% | ✗ MISS |
Latest News
Frequently Asked Questions about ZGNX
What is ZGNX's current stock price?
What is the analyst price target for ZGNX?
What sector is Zogenix, Inc. in?
What is ZGNX's market cap?
Does ZGNX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZGNX for comparison